Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer
Onco · 2021
DOI: 10.3390/onco1020007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onco, 2021. Verfasst von Gee Young Lee und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Laboratory Research and Development Service of the VA Office of Research and Development, National Center for Advancing Translational Sciences of the National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Objective
The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability.
Results
The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively.
Conclusion
LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.
Förderung
- Biomedical Laboratory Research and Development Service of the VA Office of Research and Development
- National Center for Advancing Translational Sciences of the National Institutes of Health
- National Cancer Institute
Zitieren
APA
Lee, G. Y., Mubasher, M., McKenzie, T. S., Schmitt, N. C., Sebelik, M. E., Flanagan, C. E., Osta, B. E., Cothran, M. B., & Green, H. (2021). Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. Onco. https://doi.org/10.3390/onco1020007
Vancouver
Lee GY, Mubasher M, McKenzie TS, Schmitt NC, Sebelik ME, Flanagan CE, et al. Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. Onco. 2021. doi:10.3390/onco1020007
BibTeX
@article{Lee2021,
author = {Lee, Gee Young and Mubasher, Mohamed and McKenzie, Tamra S. and Schmitt, Nicole C. and Sebelik, Merry E. and Flanagan, Carrie E. and Osta, Badi El and Cothran, Maya B. and Green, Hadiyah-Nicole},
title = {Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer},
journal = {Onco},
year = {2021},
doi = {10.3390/onco1020007}
}
EUVIMED